News & Resources

All Releases
View Summary PTC THERAPEUTICS' ANTIBACTERIAL PROGRAM RECEIVES $5 MILLION AWARD FROM THE WELLCOME TRUST
Dec 22, 2011
PDF 8.1 KB
View Summary Roche signs agreement with PTC Therapeutics to advance treatment for Spinal Muscular Atrophy (SMA)
Nov 29, 2011
PDF 12.1 KB
View Summary PTC Therapeutics Receives Grand Challenges Explorations Funding
Nov 7, 2011
PDF 8.0 KB
View Summary PTC THERAPEUTICS AND GENZYME ANNOUNCE RESTRUCTURING OF COLLABORATION
Sep 2, 2011
PDF 9.6 KB
View Summary ATALUREN PHASE 2 DATA IN NONSENSE MUTATION CYSTIC FIBROSIS PUBLISHED IN THE EUROPEAN RESPIRATORY JOURNAL
Jul 1, 2011
PDF 13.6 KB
View Summary ASTRAZENECA AND PTC THERAPEUTICS ANNOUNCE STRATEGIC ONCOLOGY DRUG DISCOVERY COLLABORATION WITH POTENTIAL EXTENSION TO OTHER THERAPEUTIC AREAS
Jun 29, 2011
PDF 9.8 KB
View Summary PTC THERAPEUTICS APPOINTS ROBERT SPIEGEL, M.D. AS CHIEF MEDICAL OFFICER
Mar 30, 2011
PDF 8.3 KB
View Summary PTC Therapeutics Announces Achievement of Milestone in BMI1 Collaboration with the Wellcome Trust
Mar 2, 2011
PDF 8.6 KB
View Summary PTC Therapeutics and Parent Project Muscular Dystrophy Advance Drug Discovery Program to Improve Heart Function in Duchenne/Becker Muscular Dystrophy Patients
Feb 1, 2011
PDF 8.5 KB
View Summary PTC THERAPEUTICS' PRESIDENT AND CEO ELECTED AAAS FELLOW
Jan 19, 2011
PDF 7.5 KB
View Summary PTC Therapeutics Completes Enrollment of Phase 3 Trial of Ataluren in Patients with Cystic Fibrosis
Dec 21, 2010
PDF 11.0 KB
View Summary Observational Data from One-Year Follow-up Study Validate Six-Minute Walk Distance as an Outcome Measure in Duchenne and Becker Muscular Dystrophy
Dec 1, 2010
PDF 10.9 KB
View Summary PTC Publishes Results From Phase 2 Study of Ataluren in Children with Cystic Fibrosis
Nov 15, 2010
PDF 11.9 KB
View Summary PTC Therapeutics Initiates Phase 2 Clinical Trial of Ataluren in Patients with Methylmalonic Acidemia
Oct 26, 2010
PDF 10.8 KB
View Summary PIVOTAL DATA PRESENTED AT THE WORLD MUSCLE SOCIETY CONGRESS SUGGEST ATALUREN SLOWS THE LOSS OF WALKING ABILITY IN PATIENTS WITH NONSENSE MUTATION DUCHENNE/BECKER MUSCULAR DYSTROPHY
Oct 15, 2010
PDF 12.9 KB
View Summary PTC THERAPEUTICS AWARDED $1.6 MILLION FDA ORPHAN DRUG GRANT TO SUPPORT AN ONGOING PHASE 3 STUDY IN CYSTIC FIBROSIS
Sep 21, 2010
PDF 9.8 KB
View Summary PTC THERAPEUTICS AWARDED $5.4 MILLION GRANT FROM THE WELLCOME TRUST
Jun 7, 2010
PDF 9.5 KB
View Summary PTC THERAPEUTICS AND GENZYME CORPORATION ANNOUNCE PRELIMINARY RESULTS FROM THE PHASE 2B CLINICAL TRIAL OF ATALUREN FOR NONSENSE MUTATION DUCHENNE/BECKER MUSCULAR DYSTROPHY
Mar 3, 2010
PDF 12.3 KB
View Summary PTC THERAPEUTICS ANNOUNCES ADDITIONAL STUDY OF ATALUREN IN PATIENTS WITH ADVANCED NONSENSE MUTATION DUCHENNE/BECKER MUSCULAR DYSTROPHY
Jan 19, 2010
PDF 12.3 KB
View Summary PTC THERAPEUTICS CLOSES $50 MILLION FINANCING
Dec 22, 2009
PDF 7.8 KB
Showing 1-20 of 32 Page: 1 2  Next 20